Evidence map›Paper›PMID 41998023›Full record

ArticleScientific reports2026

Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients.

Dietmar J Hecker, Marc K H Remke, Maximilian Linxweiler, Rhoikos Furtwängler, Yeliz Akrasu, Dominik Schöndorf, Norbert Graf, Dorothée Krieter, Nadine Oberkircher, Bernhard Schick and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dietmar J HeckerDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Hospital, 66421, Homburg, Germany. dietmar.hecker@uks.eu.
Marc K H RemkeDepartment of Pediatrics Hematology/Oncology, Saarland University Hospital, 66421, Homburg, Germany.
Maximilian LinxweilerDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Hospital, 66421, Homburg, Germany.
Rhoikos FurtwänglerDivicsion of Pediatric Hematology and Oncology, Inselspital, 3015, Bern, Switzerland.
Yeliz AkrasuDepartment of Pediatrics Hematology/Oncology, Saarland University Hospital, 66421, Homburg, Germany.
Dominik SchöndorfDepartment of Pediatrics Hematology/Oncology, Saarland University Hospital, 66421, Homburg, Germany.
Norbert GrafDepartment of Pediatrics Hematology/Oncology, Saarland University Hospital, 66421, Homburg, Germany.
Dorothée KrieterDepartment of Otorhinolaryngology, Hospital Winsen, 21423, Winsen (Luhe), Germany.
Nadine OberkircherSaarland University Medical Center, Kinder- und Jugendpsychiatrie und des Childhoodhaus Saarland, 66421, Homburg, Germany.
Bernhard SchickDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Hospital, 66421, Homburg, Germany.
Alessandro BozzatoDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Hospital, 66421, Homburg, Germany.
Arne SimonDepartment of Pediatrics Hematology/Oncology, Saarland University Hospital, 66421, Homburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In pediatric cancer patients, platinum-induced sensory hearing loss (SHL) manifests in bilateral, symmetrical loss of outer hair cells and starts at a frequency range up to 10 kHz. Hearing loss has a significant impact on education, social integration and personality development in childhood cancer survivors. Early reliable detection of hearing loss may prompt attending oncologists to change chemotherapy if a less ototoxic therapeutic alternative is available. Pediatric cancer patients (2-19 years) receiving cisplatin-, carboplatin- or vincristine-containing regimens were eligible. Ultra-high frequency pure tone audiometry (PTA) and ultra-high frequency DPOAE measurements (up to 16 kHz) were compared. A total of 153 examinations were performed in 83 consecutive patients. While only 60 PTAs yielded reliable results, 153 DPOAE examinations up to 16 kHz were informative. Significant findings were observed between 10 and 16 kHz in both PTA and DPOAE assessments. In the cisplatin group, we found a significant reduction in DPOAE levels from 13 to 16 kHz, as well as a significant increase in DPOAE levels at 2.5 kHz and 3 kHz. Treatment with VCR and carboplatin did not result in substantial SHL. Hearing measurements up to 16 kHz can reveal an early ototoxic effect. In pediatric cancer patients, DPOAE measurement (up to 16 kHz) is more feasible and reliable (compared to PTA) and can detect SHL in ultra-high frequencies (10-16 kHz) at an earlier time point.

Indexed as

Antineoplastic AgentsHearing LossNeoplasmsOtoacoustic Emissions, SpontaneousAdolescentAudiometry, Pure-ToneAuditory AcuityCarboplatinChildChild, PreschoolCisplatinFemaleHumansMaleVincristineYoung AdultAntineoplastic AgentsCarboplatinCisplatinVincristineCarboplatinCisplatinNormal hearingOtoacoustic emissionsOtotoxicityOuter hair cellsPure tone audiometrySensory hearing lossVincristine

Identifiers

PMID41998023
PMCPMC13090346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.